CW December 2002
Volume 11Issue Number 12 December 2002 ISSN 10593802 COX-2 Inhibitors Combined with Radiation Therapy Show Promise as Lung Cancer TreatmentAdding celecoxib to chemoradiotherapy appears to be a promising way to treat non-small cell lung cancer (NSCLC). Several phase II trials combining celecoxib with radiation therapy, either alone or with chemotherapy, are assessing the role of cyclooxygenase-2 (COX-2) inhibitors as potential radiosensitizers.
Go to Previous Page Go to Next Page Source & Additional Reading 20th Annual Chemotherapy Foundation Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW December 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
